

**Payal Sen, MD**Respiratory Institute, Cleveland Clinic,  
Cleveland, OH**Sumita B. Khatri, MD**Respiratory Institute, Cleveland Clinic, Cleveland,  
OH; Professor, Cleveland Clinic Lerner College  
of Medicine of Case Western Reserve University,  
Cleveland, OH**Vickram Tejawani, MD**Respiratory Institute, Cleveland Clinic,  
Cleveland, OH; Assistant Professor, Cleveland  
Clinic Lerner College of Medicine of Case  
Western Reserve University, Cleveland, OH

# Measuring exhaled nitric oxide when diagnosing and managing asthma

## ABSTRACT

Measuring the concentration of nitric oxide in the exhaled breath may have several roles in patients with suspected or confirmed asthma: as an adjunctive test for the disease, as a test to determine whether patients with asthma are likely to respond to inhaled corticosteroids, as a way to monitor and adjust this therapy, and as a way to estimate the likelihood of exacerbations. However, it is not very sensitive or specific and should not be used by itself, but rather in conjunction with clinical signs and symptoms. The authors address the role of measuring exhaled nitric oxide in the diagnosis and management of asthma and provide guidance for its appropriate use.

## KEY POINTS

Nitric oxide is produced in the airways of patients with type 2 inflammation.

The fractional concentration of exhaled nitric oxide (FeNO) can be used as an adjunctive test for asthma, but it can be raised or lowered by many extrinsic and intrinsic factors other than asthma and should not be used by itself.

Patients with asthma and high FeNO values are more likely to benefit from inhaled corticosteroid and biologic therapy.

Measuring the FeNO may be useful in adjusting the daily dose of inhaled corticosteroids in adults with asthma, both up-titration and weaning. However, data conflict on how much value this adds compared with using clinical signs alone.

**A**STHMA IS A HETEROGENEOUS pulmonary disease characterized by inflammation of the lower airways. In recent years, specific endotyping through biomarkers of airway inflammation has helped in guiding evaluation and assessment of the severity of asthma and in deciding on treatment.


One of the biomarkers is exhaled nitric oxide, which can now be measured in parts per billion (ppb). In this review, we discuss current care guidelines regarding the role of measuring exhaled nitric oxide in the evaluation and management of asthma.

## ■ TYPES OF ASTHMA

Asthma is a chronic inflammatory disorder of the airways that results physiologically in bronchial hyperreactivity, and clinically in recurrent episodes of wheezing, chest tightness, or coughing. It is a heterogeneous disease with distinct mechanistic pathways (endotypes) and variable clinical presentations (phenotypes). Regarding endotypes, we can classify cases of asthma according to levels of type 2 (T2) inflammation:

- T2-high, with high levels of interleukin (IL)-4, IL-5, and IL-13, inflammation, and exhaled nitric oxide; it tends to respond to treatment with inhaled corticosteroids
- T2-low, with lower levels of the above, but higher levels of IL-1-beta and IL-6; it tends to resist treatment with inhaled corticosteroids.

This dichotomy has shaped our thinking about the pathobiology and biochemistry of asthma. Type 2 cytokines (IL-4, IL-5, and



**Figure 1.** Inflammatory cytokines interleukin (IL)-13, IL-1-beta, and tumor necrosis factor alpha (TNF-alpha) are upregulated in response to tissue damage and induce expression of the inducible nitric oxide synthase (iNOS) gene, leading to a more sustained release of nitric oxide (NO).

NADP = nicotinamide adenine dinucleotide phosphate; NADPH = reduced form of NADP; NO<sub>2</sub> = nitrite; NO<sub>3</sub> = nitrate; ONOO = peroxynitrite; Th2 = T helper cell type 2

IL-13) are produced by CD4-positive T cells; IL-5 is also produced by CD8-positive T cells and natural killer cells, and IL-13 is also produced by innate lymphoid cells.<sup>1</sup> IL-4 also increases IL-13 production, which contributes to the physiologic features of asthma such as mucus production and airway fibrosis and hyperresponsiveness.<sup>2</sup>

## ■ NITRIC OXIDE IS A PRODUCT OF TYPE 2 INFLAMMATION

Nitric oxide in exhaled breath is produced in the airways by nitric oxide synthase. The inducible isoform of nitric oxide synthase is a mediator of eosinophilic

airway inflammation. In T2-high asthma, IL-13 upregulates inducible nitric oxide synthase, leading to increased nitric oxide production. This increased nitric oxide production worsens type 2 inflammation and contributes to airway remodeling and narrowing.<sup>3</sup> In people with asthma, the amount of nitric oxide in the breath is proportionate to the number of eosinophils in the sputum, peak flow variability, and hyperresponsiveness to methacholine, and it is reduced by both inhaled and oral corticosteroids.<sup>4,5</sup>

In 2007, Suresh et al<sup>6</sup> performed the first known direct measurement of nitric oxide released from human bronchial epithelial cells. They demonstrated that stimulation with IL-13 results in a significant increase

in nitric oxide production by inducing inducible nitric oxide synthase and alters nitric oxide metabolism, resulting in an increase in the amount of nitrate relative to nitrite (**Figure 1**). They concluded that the bronchial epithelium is the likely source of nitric oxide in the exhaled breath, and that increased levels observed in inflammatory diseases such as asthma are likely due to inducible nitric oxide synthase upregulation.<sup>6</sup> Notably, other inflammatory cytokines such as IL-1-beta and tumor necrosis factor alpha can also upregulate inducible nitric oxide synthase and subsequently increase exhaled nitric oxide, reducing the specificity of nitric oxide for type 2 cytokines such as IL-13.<sup>7</sup>

In 1998, Dweik et al<sup>8</sup> showed that oxygen regulates nitric oxide levels through effects on the kinetics of nitric oxide synthase and proposed that nitric oxide synthase is a mediator of the vascular response to oxygen in the lung.

## ■ NITRIC OXIDE AS AN ADJUNCTIVE DIAGNOSTIC TEST FOR ASTHMA

Asthma is typically diagnosed clinically, but this can sometimes be challenging because asthma is episodic and lacks a gold standard diagnostic test. Numerous studies have evaluated the diagnostic accuracy of measuring exhaled nitric oxide compared with established diagnostic standards such as bronchial provocation, postbronchodilator forced expiratory volume in 1 second, peak-flow variability, or a combination of these.<sup>9</sup>

Karrasch and colleagues<sup>9</sup> performed a systematic review and meta-analysis of 26 such studies and reported that nitric oxide testing had an overall 65% sensitivity (95% confidence interval 58%–72%) and 82% specificity (95% confidence interval 76%–86%) for diagnosing asthma. Higher cutoff values were more specific, while there was no association with sensitivity.

However, confounding factors that increase or decrease nitric oxide need to be considered. Values can be elevated by chronic rhinosinusitis, nasal polyposis, atopy without other features of asthma, rhinovirus respiratory infections, exposure to air pollution, or in patients who are male, older, or taller.<sup>10,11</sup> Conversely, factors that can reduce exhaled nitric oxide include cigarette smoking, inhaled corticosteroid use, alcohol use, strenuous exercise, and drugs such as leukotriene receptor antagonists and prostaglandins (**Table 1**).<sup>11</sup>

Nitric oxide testing increases the accuracy of asthma diagnosis and is most reliable in patients who are not taking corticosteroids.<sup>12</sup> Elevated nitric oxide levels may complement the clinical history and spirometry testing to support the diagnosis of asthma, particularly when clinical suspicion is high. Conversely, low levels

can help exclude asthma in the setting of normal spirometry and no suggestive symptoms.

A systematic review of 32 studies (24 in adults, 8 in children) concluded that nitric oxide measurement, bronchodilator reversibility, blood eosinophils, or immunoglobulin E should not be used individually to diagnose asthma, since using them as stand-alone tests has limited accuracy.<sup>13</sup> Therefore, expert opinion is that nitric oxide measurement should be used in conjunction with testing for variable airflow limitation to support the diagnosis of asthma.<sup>14</sup>

## Expert society recommendations

**The National Asthma Education and Prevention Program**<sup>15</sup> recommends that if nitric oxide is measured, it should be done as part of an ongoing monitoring and management strategy. This group also makes a conditional recommendation that if the diagnosis of asthma is uncertain, one can measure nitric oxide as an adjunct to the evaluation. Although there is limited evidence for an exact cutoff point, this group notes that a fractional concentration of exhaled nitric oxide (FeNO) higher than 50 ppb is consistent with type 2 inflammation<sup>15</sup> and supports a diagnosis of asthma (other guidelines use a cutoff point of 40 ppb),<sup>16,17</sup> whereas a concentration lower than 25 ppb suggests a diagnosis other than asthma.

**The British Thoracic Society and the Global Initiative for Asthma** favor measuring nitric oxide as an adjunctive tool to diagnose type 2 inflammation<sup>18</sup> or to support starting an inhaled corticosteroid.<sup>19</sup> The Global Initiative for Asthma highlights the limitation of confounding features of testing—ie, exhaled nitric oxide can be elevated in nonasthmatic conditions like eosinophilic bronchitis, atopy, allergic rhinitis, and eczema and may be normal in T2-low asthma.

**The European Respiratory Society**<sup>20</sup> recommends that if the diagnosis is not clear based on initial bronchodilator reversibility testing, nitric oxide should be measured as part of the diagnostic workup in adults over age 18. A cutoff point of 50 ppb has a high specificity (> 90%) and supports a diagnosis of asthma, but high exhaled nitric oxide levels themselves do not define asthma, and conversely, a value lower than 40 ppb does not rule out asthma.<sup>20</sup> FeNO is also low during bronchoconstriction and the early phases of the allergic response and can be variable during viral respiratory infections.

In conclusion, exhaled nitric oxide measurement should not be used in isolation, and current guidelines emphasize the importance of incorporating clinical history, physical examination, and spirom-

TABLE 1  
Factors other than asthma that raise or lower the fractional concentration of exhaled nitric oxide (FeNO)

Factors that increase FeNO	Factors that decrease FeNO
<p><b>Chronic rhinosinusitis, nasal polyposis, or both:</b> FeNO is increased in patients with allergic rhinitis or nasal polyposis even in the absence of a concomitant asthma diagnosis. Patients with allergic rhinitis have higher FeNO levels than patients with nonallergic rhinitis. Perennial sensitization leads to higher FeNO than seasonal allergens.</p> <p><b>Atopy:</b> Acute exposure to allergens can increase FeNO by up to 50%.</p> <p><b>Rhinovirus respiratory infections</b> can increase FeNO by 50% to 150% through inducible nitric oxide synthase upregulation. However, not all viral infections increase FeNO—respiratory syncytial virus and influenza reduce FeNO, and bacterial infections of the respiratory tract do not affect FeNO.</p> <p><b>Nitrate-containing foods</b> such as beetroot can increase FeNO levels by 20% to 60%.</p> <p><b>Air pollution (particulate matter and ozone),</b> possibly because of oxidative potential, even in the absence of asthma.</p> <p><b>Male sex:</b> association is consistent after adjustment for height.</p> <p><b>HIV infection</b> is associated independently with raised FeNO after adjusting for use of airway medication, blood eosinophil counts, and immunoglobulin E.</p> <p><b>Increasing age:</b> Effect is greater in people over age 60 or 64, but data conflict in adults and are more consistent in children.</p> <p><b>Increased height,</b> because of increases in airway mucosal surface area.</p>	<p><b>Cigarette smoking</b> decreases FeNO by 40% to 60%. Magnitude of reduction correlates with the cumulative lifetime cigarette consumption. The effect of cigarette smoking may be reversible, but has not been reported consistently. Smokers with asthma have higher FeNO levels than healthy smokers. In clinical practice, look for intraindividual changes.</p> <p><b>Inhaled steroid use.</b> FeNO generally is sensitive to inhaled steroids and therefore will be low in most patients who are adherent to treatment.</p> <p><b>Alcohol ingestion</b>—Avoid before testing.</p> <p><b>Spirometry</b> may cause a marginal decrease. The effect is of minor importance in clinical practice, but one preferably should measure FeNO before spirometry.</p> <p><b>Certain drugs</b></p> <ul style="list-style-type: none"><li>• Leukotriene receptor antagonists</li><li>• Prostaglandins: inhaled prostaglandin E2 and iloprost downregulate inducible nitric oxide synthase expression.</li></ul> <p><b>Physical exercise</b>—Avoid strenuous exercise before testing.</p> <p><b>UNCERTAIN EFFECT</b></p> <p><b>Menstrual cycle</b> FeNO levels may vary, but this is not a consistent finding.</p>

Reprinted from Chest 2022; 161(4):906-917, Rupani H, Kent BD. Using fractional exhaled nitric oxide measurement in clinical asthma management, with permission from Elsevier.

etry testing when it is used.<sup>12</sup> Its overall specificity is higher than its sensitivity, which indicates it is more useful for ruling in than for ruling out the diagnosis of asthma.


HIGH NITRIC OXIDE PREDICTS RESPONSE TO STEROIDS

Managing asthma requires addressing environmental factors, ensuring adherence and understanding of the disorder in patients, and partnering with them on goals of care and quality of life. Guidelines recommend increasing the dose of corticosteroids as needed to control symptoms and reduce exacerbations. However, this approach can often lead to patients being on a high dose of corticosteroids without completely attaining benefits.

Like eosinophils in the sputum, nitric oxide in the breath is a good predictor of response to corticosteroid treatment.<sup>21</sup> Smith et al<sup>21</sup> showed that in patients with respiratory symptoms, especially asthma, those with values higher than 47 ppb had a higher likelihood of responding to steroids. High nitric oxide is a better predictor of steroid responsiveness than bronchodilator reversibility, peak flow variability, or airway hyperresponsiveness.<sup>21–23</sup> Patients with high nitric oxide levels who have never taken steroids have a better clinical response to them, manifested as improved symptoms and lung function.<sup>21</sup>

Exhaled nitric oxide is reduced by inhaled corticosteroid therapy, but the magnitude of reduction does not necessarily correlate with clinical response.<sup>24</sup>

Nitric oxide levels can also help to guide step-down treatment with inhaled corticosteroids. A meta-analy-



**Figure 2.** Algorithm for clinical use of measurements of the fractional concentration of exhaled nitric oxide (FeNO).

Adapted from reference 11.

sis revealed that in patients on an inhaled corticosteroid and with FeNO levels less than 50 ppb, reducing the dose gradually did not lead to increased exacerbations. However, reducing the dosage in patients with an FeNO of 50 ppb or higher did lead to increased exacerbations.<sup>25</sup> Generally speaking, for those on inhaled corticosteroids, a high FeNO does not necessarily suggest a benefit from inhaled corticosteroids, but a low FeNO suggests that increasing the inhaled corticosteroid dose may not be useful (Figure 2).<sup>11,26</sup>

## NITRIC OXIDE PREDICTS EXACERBATIONS

The risk of exacerbations also seems to correlate with a higher FeNO in patients with severe asthma. Kupczyk et al<sup>27</sup> found that patients with a baseline FeNO higher than 45 ppb had a rate of exacerbations per year nearly 6 times higher than those with a lower FeNO.<sup>27</sup> Lehtimäki et al<sup>26</sup> performed a systematic review and reported that patients with lower FeNO values while on inhaled corticosteroid therapy “probably” have a low risk of subsequent exacerbations.

The risk of exacerbations can be predicted more accurately by taking peripheral blood eosinophilia into account along with the nitric oxide level. Soma et al<sup>28</sup> found that patients with eosinophil counts of  $0.3 \times 10^9/L$  or higher and FeNO of 25 ppb or higher were more likely to have an exacerbation compared with those with low levels of both.

Data conflict on exactly how useful nitric oxide testing is in predicting exacerbations in patients with severe asthma. Studies in the United Kingdom showed the Asthma Control Questionnaire was a better predictor of exacerbations than nitric oxide.<sup>29</sup> The Liberty Asthma Quest trial<sup>30</sup> and a study in a Japanese cohort<sup>28</sup> with severe asthma showed that the combination of high blood eosinophil counts and a high FeNO could identify patients prone to frequent exacerbations.

In short, measuring nitric oxide has both prognostic and therapeutic value. The National Asthma Education and Prevention Program<sup>15</sup> emphasizes that although nitric oxide measurement can be used in choosing, monitoring, and adjusting steroid therapy, it should be an adjunct to other management and monitoring strategies.

## NITRIC OXIDE SUPPRESSION AS A TEST OF TREATMENT ADHERENCE

In 2014, the definition of severe asthma was updated to distinguish between difficult-to-treat asthma and severe asthma.<sup>31</sup> Asthma is called “difficult to treat” if it remains uncontrolled despite treatment with high-dose inhaled corticosteroids or other controller medications, or requires this level of treatment to remain well controlled. It is called “severe” if it requires treatment with high doses of an inhaled corticosteroid plus



a second controller, systemic corticosteroids, or both to prevent it from becoming uncontrolled, or if it remains uncontrolled despite this therapy. Up to 17% of asthma cases are classified as difficult to treat, and 4% to 8% are considered severe.<sup>32</sup>

Some asthma patients who are prescribed appropriate inhaler therapy and still experience frequent exacerbations are not using their inhalers or are not using them properly. Failure to recognize nonadherence or improper inhaler technique can lead to a vicious cycle of dose escalation and systemic steroid prescriptions, thus leading to potentially avoidable adverse effects of steroid therapy.

Nonadherence to inhaled corticosteroid therapy can contribute to poor asthma control but is sometimes challenging to prove. Measuring nitric oxide after directly observed inhaled corticosteroid administration can serve as an objective method to find out whether patients with difficult-to-treat asthma are adhering to treatment.

In a study in 28 patients with mild asthma, Khariitonov et al<sup>33</sup> found that nitric oxide levels decreased within a few days of starting inhaled corticosteroid therapy, and increased again after steroid withdrawal.

McNicholl et al<sup>34</sup> recruited 22 patients with difficult-to-treat asthma and an FeNO higher than 45 ppb and classified them as adherent or nonadherent based on whether they had filled more than 80% or less than 50% of their prescriptions. After 7 days of directly observed inhaled corticosteroid therapy, the nonadherent patients had a greater reduction in FeNO, to 47% vs 79% of their baseline values ( $P = .003$ ). However, the authors calculated that a 5-day test would work nearly as well as a 7-day test (area under the receiver-operating curve 0.86 vs 0.88). They validated the 5-day test in a larger group of 40 patients using a 42% or greater drop in FeNO as the number to detect nonadherence. Compared with prescription-filling records and plasma steroid levels, the nitric oxide test demonstrated reasonable discriminatory ability (sensitivity 0.67 [95% CI 0.44–0.84] and specificity 0.95 [95% CI 0.78–0.99]).<sup>34</sup>

Therefore, nitric oxide suppression testing may have a role in identifying patients who are not adhering to inhaled corticosteroid therapy and, in particular, those who fill their prescriptions but do not actually take the medication.<sup>35,36</sup>

Devices for measuring FeNO at home have been developed, such as the Niox VERO. A study by Heaney et al<sup>37</sup> showed that using these devices during maintenance inhaled corticosteroid therapy resulted in significant reductions in FeNO and blood eosin-

ophil counts and increases in forced expiratory volume in 1 second and asthma-control questionnaire scores.<sup>37</sup>

Thus, nitric oxide suppression testing may identify patients who may have been labeled as having difficult-to-control asthma but who were not receiving inhaled corticosteroid therapy (due to either nonadherence or poor inhaler technique). These patients may thus be spared escalating steroid doses and subsequent side effects. However, since evidence is sparse in patients without severe asthma, the National Asthma Education and Prevention Program recommends against using nitric oxide as a measure of adherence in them, and the role of nitric oxide suppression for checking adherence is limited to patients with severe asthma.<sup>15</sup>

## NITRIC OXIDE MAY PREDICT RESPONSE TO BIOLOGIC THERAPY

Most studies have used peripheral eosinophilia to characterize the T2-high asthma endotype, but elevated exhaled nitric oxide can also serve as an indicator of a T2-high endotype. Consistent with this, elevated nitric oxide has been shown to predict a favorable response to biologic therapies, and low nitric oxide has been shown to predict less improvement with biologic therapy.<sup>38</sup> This ability to predict response may confer a cost-saving benefit.<sup>39</sup>

Notably, in a post hoc analysis, patients with elevated nitric oxide (FeNO  $\leq 25$  ppb) and peripheral eosinophilia (eosinophil counts  $> 0.150 \times 10^9/L$ ) had a greater reduction in exacerbations with mepolizumab than those with peripheral eosinophilia alone.<sup>40</sup> Patients with high FeNO also derived greater benefit from tezepelumab, although those with an FeNO lower than 25 ppb did have a reduction in exacerbations.<sup>41</sup> McDowell et al,<sup>42</sup> in a prospective observational study, showed that the exhaled nitric oxide level during an exacerbation is useful in discriminating between eosinophilic and noneosinophilic exacerbations in patients treated with mepolizumab. They suggested that nitric oxide be measured during exacerbations and that if FeNO is low ( $\leq 20$  ppb), oral steroids may be of limited utility and antibiotics alone should be considered. Conversely, a high FeNO ( $\geq 50$  ppb) provides support for giving oral steroids.<sup>42</sup>

## ANOTHER TOOL, BUT NOT THE ONLY TOOL

The level of exhaled nitric oxide should be combined with other measures to assess asthma control and should be interpreted within the context of the pretest

TABLE 2

**How is measuring exhaled nitric oxide useful in asthma?**

Elevated fractional concentration of exhaled nitric oxide (FeNO) serves as an adjunct to history, physical examination, and spirometry testing to help with the diagnosis of asthma and is most reliable in patients who have never received steroids.

Conversely, low FeNO can help exclude asthma in the setting of normal spirometry and no suggestive symptoms.

High FeNO is an indicator of a T2-high phenotype and can predict response to inhaled corticosteroids and biologic therapies.

High FeNO is a predictor of increased exacerbation risks and accelerated decline in lung function.

FeNO can be used to monitor adherence and compliance with treatment.

Low FeNO can help to step down asthma treatment with inhaled corticosteroids.

**Factors limiting the interpretation of FeNO**

FeNO should not be used in isolation, and clinical history, physical examination, and spirometry testing should be incorporated.

Many factors other than asthma can raise or lower FeNO (See Table 1).

FeNO is also lower during bronchoconstriction and in the early phases of allergic response.

FeNO can be variable during viral respiratory infections.

probability.<sup>43,44</sup> If there are no confounding factors, a low level of exhaled nitric oxide suggests that a response to corticosteroids is unlikely, whereas a high level suggests that a response to corticosteroids is likely. Ultimately, however, it is the individual clinician who identifies persistent inflammation and decides on initiating or stepping down corticosteroid therapy.

In summary, exhaled nitric oxide should not be the sole tool used to diagnose asthma, although when used

in the right clinical context, it can support the diagnosis of asthma, predict the response to inhaled corticosteroid therapy, monitor compliance, and predict the prognosis of asthma (Table 2). ■

**DISCLOSURES**

The authors report no relevant financial relationships which, in the context of their contributions, could be perceived as a potential conflict of interest.

**REFERENCES**

- Hammad H, Lambrecht BN. The basic immunology of asthma [published correction appears in *Cell* 2021; 184(9):2521–2522]. *Cell* 2021; 184(6):1469–1485. doi:10.1016/j.cell.2021.02.016
- Gour N, Wills-Karp M. IL-4 and IL-13 signaling in allergic airway disease. *Cytokine* 2015; 75(1):68–78. doi:10.1016/j.cyt.2015.05.014
- Ricciardolo FL. Multiple roles of nitric oxide in the airways. *Thorax* 2003; 58(2):175–182. doi:10.1136/thorax.58.2.175
- Matsunaga K, Hirano T, Akamatsu K, Minakata Y. Predictors for identifying the efficacy of systemic steroids on sustained exhaled nitric oxide elevation in severe asthma. *Allergol Int* 2013; 62(3):359–365. doi:10.2332/allergolint.12-OA-0530
- Neelamegan R, Saka V, Tamilarasu K, Rajaram M, Selvarajan S, Chandrasekaran A. Clinical utility of fractional exhaled nitric oxide (FeNO) as a biomarker to predict severity of disease and response to inhaled corticosteroid (ICS) in asthma patients. *J Clin Diagn Res* 2016; 10(12):FC01–FC06. doi:10.7860/JCDR/2016/20656.8950
- Suresh V, Mih JD, George SC. Measurement of IL-13-induced iNOS-derived gas phase nitric oxide in human bronchial epithelial cells. *Am J Respir Cell Mol Biol* 2007; 37(1):97–104. doi:10.1165/rcmb.2006-0419OC
- Luheshi NM, Rothwell NJ, Brough D. Dual functionality of interleukin-1 family cytokines: implications for anti-interleukin-1 therapy. *Br J Pharmacol* 2009; 157(8):1318–1329. doi:10.1111/j.1476-5381.2009.00331.x
- Dweik RA, Laskowski D, Abu-Soud HM, et al. Nitric oxide synthesis in the lung. Regulation by oxygen through a kinetic mechanism. *J Clin Invest* 1998; 101(3):660–666. doi:10.1172/JCI1378
- Karrasch S, Linde K, Rücker G, et al. Accuracy of FeNO for diagnosing asthma: a systematic review. *Thorax* 2017; 72(2):109–116. doi:10.1136/thoraxjnl-2016-208704
- Scott M, Raza A, Karmaus W, et al. Influence of atopy and asthma on exhaled nitric oxide in an unselected birth cohort study. *Thorax* 2010; 65(3):258–262. doi:10.1136/thx.2009.125443
- Rupani H, Kent BD. Using fractional exhaled nitric oxide measurement in clinical asthma management. *Chest* 2022; 161(4):906–917. doi:10.1016/j.chest.2021.10.015
- Loewenthal L, Menzies-Gow A. FeNO in asthma. *Semin Respir Crit Care Med* 2022; 43(5):635–645. doi:10.1055/s-0042-1743290
- Korevaar DA, Westerhof GA, Wang J, et al. Diagnostic accuracy of minimally invasive markers for detection of airway eosinophilia in asthma: a systematic review and meta-analysis. *Lancet Respir Med* 2015; 3(4):290–300. doi:10.1016/S2213-2600(15)00050-8
- Heffler E, Carpagnano GE, Favero E, et al. Fractional exhaled nitric oxide (FeNO) in the management of asthma: a position paper of the Italian Respiratory Society (SIP/IRS) and Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC). *Multidiscip Respir Med* 2020; 15(1):36. doi:10.4081/mrm.2020.36
- Expert Panel Working Group of the National Heart, Lung, and Blood Institute (NHLBI) administered and coordinated National

- Asthma Education and Prevention Program Coordinating Committee (NAEPCC), Cloutier MM, Baptist AP, et al. 2020 focused updates to the asthma management guidelines: a report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group [published correction appears in *J Allergy Clin Immunol* 2021; 147(4):1528–1530]. *J Allergy Clin Immunol* 2020; 146(6): 1217–1270. doi:10.1016/j.jaci.2020.10.003
16. Kuo CR, Spears M, Haughney J, et al. Scottish consensus statement on the role of FeNO in adult asthma. *Respir Med* 2019; 155:54–57. doi:10.1016/j.rmed.2019.07.010
17. Drake SM, Simpson A, Fowler SJ. Asthma Diagnosis: The changing face of guidelines. *Pulm Ther* 2019; 5(2):103–115. doi:10.1007/s41030-019-0093-y
18. British Thoracic Society; Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. *Thorax* 2014; 69 suppl 1:1–192. PMID:25323740
19. Ish P, Malhotra N, Gupta N. GINA 2020: what's new and why? *J Asthma* 2021; 58(10):1273–1277. doi:10.1080/02770903.2020.1788076
20. Louis R, Satia I, Ojanguren I, et al. European Respiratory Society guidelines for the diagnosis of asthma in adults [published online ahead of print, 2022 Feb 15]. *Eur Respir J* 2022; 2101585. doi:10.1183/13993003.01585-2021
21. Smith AD, Cowan JO, Brassett KP, et al. Exhaled nitric oxide: a predictor of steroid response. *Am J Respir Crit Care Med* 2005; 172(4):453–459. doi:10.1164/rccm.200411-1498OC
22. Szefer SJ, Martin RJ, King TS, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. *J Allergy Clin Immunol* 2002; 109(3):410–418. doi:10.1067/mai.2002.122635
23. Knuffman JE, Sorkness CA, Lemanske RF Jr, et al. Phenotypic predictors of long-term response to inhaled corticosteroid and leukotriene modifier therapies in pediatric asthma. *J Allergy Clin Immunol* 2009; 123(2):411–416. doi:10.1016/j.jaci.2008.11.016
24. Cowan DC, Taylor DR, Peterson LE, et al. Biomarker-based asthma phenotypes of corticosteroid response. *J Allergy Clin Immunol* 2015; 135(4):877–883.e1. doi:10.1016/j.jaci.2014.10.026
25. Wang K, Verbakel JY, Oke J, et al. Using fractional exhaled nitric oxide to guide step-down treatment decisions in patients with asthma: a systematic review and individual patient data meta-analysis. *Eur Respir J* 2020; 55:1902150. doi:10.1183/13993003.02150-2019
26. Lehtimäki L, Csonka P, Mäkinen E, Isojärvi J, Hovi SL, Ahovuo-Saloranta A. Predictive value of exhaled nitric oxide in the management of asthma: a systematic review. *Eur Respir J* 2016; 48(3):706–714. doi:10.1183/13993003.00699-2016
27. Kupczyk M, ten Brinke A, Sterk PJ, et al. Frequent exacerbators—a distinct phenotype of severe asthma. *Clin Exp Allergy* 2014; 44(2):212–221. doi:10.1111/cea.12179
28. Soma T, Iemura H, Naito E, et al. Implication of fraction of exhaled nitric oxide and blood eosinophil count in severe asthma. *Allergol Int* 2018; 67S:S3–S11. doi:10.1016/j.alit.2018.04.003
29. Ryan D, Heatley H, Heaney LG, et al. Potential severe asthma hidden in UK primary care [published correction appears in *J Allergy Clin Immunol Pract* 2021; 9(11):4182]. *J Allergy Clin Immunol Pract* 2021; 9(4):1612–1623.e9. doi:10.1016/j.jaip.2020.11.053
30. Busse WW, Wenzel SE, Casale TB, et al. Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis. *Lancet Respir Med* 2021; 9(10):1165–1173. doi:10.1016/S2213-2600(21)00124-7
31. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma [published correction appears in *Eur Respir J* 2014; 43(4):1216. Dosage error in article text] [published correction appears in *Eur Respir J*. 2018; 52(1)] [published correction appears in *Eur Respir J* 2022; 59(6)]. *Eur Respir J* 2014; 43(2):343–373. doi:10.1183/09031936.00202013
32. Rönneberg L, Axelsson M, Kankaanranta H, et al. Severe asthma in a general population study: prevalence and clinical characteristics. *J Asthma Allergy* 2021; 14:1105–1115. doi:10.2147/JAA.S327659
33. Kharitonov SA, Donnelly LE, Montuschi P, Corradi M, Collins JV, Barnes PJ. Dose-dependent onset and cessation of action of inhaled budesonide on exhaled nitric oxide and symptoms in mild asthma. *Thorax* 2002; 57(10):889–896. doi:10.1136/thorax.57.10.889
34. McNicholl DM, Stevenson M, McGarvey LP, Heaney LG. The utility of fractional exhaled nitric oxide suppression in the identification of nonadherence in difficult asthma. *Am J Respir Crit Care Med* 2012; 186(11):1102–1108. doi:10.1164/rccm.201204-0587OC
35. Butler CA, Heaney LG. Fractional exhaled nitric oxide and asthma treatment adherence. *Curr Opin Allergy Clin Immunol* 2021; 21(1):59–64. doi:10.1097/ACI.0000000000000704
36. Knoery C, Brockway B, Cowan J, Cox E, Taylor R. Non-adherence to inhaled corticosteroid therapy as an explanation for persistently elevated exhaled nitric oxide levels in patients with asthma: effect of directly observed therapy with inhaled corticosteroids (DOT-ICS). *Eur Respir J* 2015; 46(suppl 59):PA3999. doi:10.1183/13993003.congress-2015.PA3999
37. Heaney LG, Busby J, Bradding P, et al. Remotely monitored therapy and nitric oxide suppression identifies nonadherence in severe asthma. *Am J Respir Crit Care Med* 2019; 199(4):454–464. doi:10.1164/rccm.201806-1182OC
38. Casale TB, Luskin AT, Busse W, et al. Omalizumab effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, a prospective real-world study. *J Allergy Clin Immunol Pract* 2019; 7(1):156–164.e1. doi:10.1016/j.jaip.2018.04.043
39. Brooks EA, Massanari M, Hanania NA, Weiner DJ. Cost-effectiveness of fractional exhaled nitric oxide (FeNO) measurement in predicting response to omalizumab in asthma. *Clinicoecon Outcomes Res* 2019; 11:301–307. doi:10.2147/CEOR.S177207
40. Shrimanker R, Keene O, Hynes G, Wenzel S, Yancey S, Pavord ID. Prognostic and predictive value of blood eosinophil count, fractional exhaled nitric oxide, and their combination in severe asthma: a post hoc analysis. *Am J Respir Crit Care Med* 2019; 200(10):1308–1312. doi:10.1164/rccm.201903-0599LE
41. Menzies-Gow A, Colice G, Griffiths JM, et al. NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma. *Respir Res* 2020; 21(1):266. doi:10.1186/s12931-020-01526-6
42. McDowell PJ, Diver S, Yang F, et al. The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study. *Lancet Respir Med* 2021; 9(10):1174–1184. doi:10.1016/S2213-2600(21)00004-7
43. Khatri SB, Iaccarino JM, Barochia A, et al. Use of fractional exhaled nitric oxide to guide the treatment of asthma: an official American Thoracic Society clinical practice guideline. *Am J Respir Crit Care Med* 2021; 204(10):e97–e109. doi:10.1164/rccm.202109-2093ST
44. Murphy RC, Zhang P, Tejwani V, et al. Summary for clinicians: clinical practice guideline for the use of fractional exhaled nitric oxide to guide the treatment of asthma. *Ann Am Thorac Soc* 2022; 19(10):1627–1630. doi:10.1513/AnnalsATS.202204-289CME

Address: Payal Sen, MD, Respiratory Institute, A90, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; senp@ccf.org